methylprednisolone hemisuccinate has been researched along with Multiple Sclerosis in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allon, N; Barenholz, Y; Bavli, Y; Katzir, TB; Kizelsztein, P; Ovadia, H; Raviv, U; Sasson, E; Schilt, Y; Turjeman, K | 1 |
| Furutama, D; Kimura, F; Maeda, T; Ohsawa, N; Shinoda, K; Tanaka, T | 1 |
| Avnir, Y; Barenholz, Y; Gabizon, A; Kizelsztein, P; Sigal, A; Tulchinsky, D; Turjeman, K; Tzemach, D | 1 |
| Burgdorff, T; Landthaler, M; Stolz, W; Venemalm, L; Vogt, T | 1 |
| Beck, RW; Bhatti, MT; Brodsky, MC; Buckley, EG; Chrousos, GA; Corbett, J; Eggenberger, E; Gal, RL; Goodwin, JA; Katz, B; Kaufman, DI; Keltner, JL; Kupersmith, MJ; Miller, NR; Moke, PS; Nazarian, S; Orengo-Nania, S; Savino, PJ; Shults, WT; Smith, CH; Trobe, JD; Wall, M; Xing, D | 1 |
| Kaliciak-Kempińska, A; Mazur-Chłodek, L | 1 |
| Chan, SC; Dmitrovic, J; Metz, LM; Morrow, SA; Stoian, CA | 1 |
| Fernandez-Barreiro, A; Gomez-Gallego, M; Meca-Lallana, J | 1 |
| Kikukawa, M; Ootsuka, K; Sasaki, O; Taguchi, K | 1 |
| Barkhof, F; Braam, M; Frequin, ST; Hommes, OR; Wevers, RA | 1 |
| Beck, RW; Trobe, JD | 1 |
| Cross, AH; Devere, TR; Trotter, JL | 1 |
| Carroll, DJ; Catz, I; Warren, KG | 1 |
| Ochudło, S | 1 |
1 review(s) available for methylprednisolone hemisuccinate and Multiple Sclerosis
| Article | Year |
|---|---|
Effects of high-to-mega-dose synthetic corticosteroids on multiple sclerosis patients with special reference to cerebrospinal fluid antibodies to myelin basic protein.
Topics: Antibodies; Dose-Response Relationship, Drug; Humans; Methylprednisolone; Methylprednisolone Hemisuccinate; Multiple Sclerosis; Myelin Basic Protein; Prednisone | 1987 |
5 trial(s) available for methylprednisolone hemisuccinate and Multiple Sclerosis
| Article | Year |
|---|---|
High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial.
Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents; Brain; Cohort Studies; Female; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone Hemisuccinate; Middle Aged; Multiple Sclerosis; Optic Neuritis; Prednisone; Prospective Studies; Risk Factors; Sex Factors; United States | 2003 |
The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Area Under Curve; Biological Availability; Biotransformation; Female; Humans; Immunosuppressive Agents; Infusions, Intravenous; Liver; Male; Methylprednisolone; Methylprednisolone Hemisuccinate; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prednisolone; Prednisone | 2004 |
What we have learned from the Optic Neuritis Treatment Trial.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents; Brain; Female; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Male; Methylprednisolone Hemisuccinate; Middle Aged; Multiple Sclerosis; Optic Neuritis; Prednisolone; Treatment Outcome; Visual Acuity | 1995 |
Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group.
Topics: Administration, Oral; Adolescent; Adult; Cohort Studies; Color Perception; Contrast Sensitivity; Female; Follow-Up Studies; Glucocorticoids; Humans; Incidence; Injections, Intravenous; Male; Methylprednisolone Hemisuccinate; Middle Aged; Multiple Sclerosis; Optic Neuritis; Prednisone; Recurrence; Visual Acuity; Visual Fields | 1997 |
[Effect of treatment with Encorton (Polfa), Solu-Medrol and Encorton and Cyclophosphamide and Encorton on the production of immunoglobulin G in the central nervous system in multiple sclerosis].
Topics: Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunoglobulin G; Methylprednisolone; Methylprednisolone Hemisuccinate; Multiple Sclerosis; Poland; Prednisone | 1989 |
9 other study(ies) available for methylprednisolone hemisuccinate and Multiple Sclerosis
| Article | Year |
|---|---|
Nano-Drugs Based on Nano Sterically Stabilized Liposomes for the Treatment of Inflammatory Neurodegenerative Diseases.
Topics: Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Apolipoproteins E; Cyclic N-Oxides; Disease Models, Animal; Drug Delivery Systems; Encephalomyelitis, Autoimmune, Experimental; Inflammation; Liposomes; Methylprednisolone Hemisuccinate; Mice; Multiple Sclerosis; Nanoparticles; Neurodegenerative Diseases; Prodrugs; Tissue Distribution | 2015 |
Recurrent high-dose intravenous methylprednisolone succinate pulse therapy-induced hepatopathy in a patient with multiple sclerosis.
Topics: Chemical and Drug Induced Liver Injury; Child; Female; Glucocorticoids; Humans; Infusions, Intravenous; Liver Function Tests; Methylprednisolone Hemisuccinate; Multiple Sclerosis; Pulse Therapy, Drug; Treatment Outcome | 2011 |
Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids.
Topics: Animals; Capsules; Chemical Phenomena; Chemistry, Pharmaceutical; Encephalomyelitis, Autoimmune, Experimental; Female; Glucocorticoids; Humans; Hydrophobic and Hydrophilic Interactions; Leukemia; Liposomes; Lymphoma, T-Cell; Methylprednisolone Hemisuccinate; Mice; Multiple Sclerosis; Myelin Proteolipid Protein; Nanostructures; Solubility; Water | 2011 |
IgE-mediated anaphylactic reaction induced by succinate ester of methylprednisolone.
Topics: Adult; Anaphylaxis; Anti-Inflammatory Agents; Humans; Immunoglobulin E; Injections, Intravenous; Male; Methylprednisolone Hemisuccinate; Multiple Sclerosis; Skin Tests | 2002 |
[Side effects during treatment with Solu-Medrol for optic neuritis in the course of MS].
Topics: Adult; Female; Headache; Humans; Leukocyte Disorders; Methylprednisolone Hemisuccinate; Multiple Sclerosis; Nausea; Neuroprotective Agents; Optic Neuritis | 2003 |
Multiple sclerosis onset during etanercept treatment.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Etanercept; Female; Glucocorticoids; Humans; Immunoglobulin G; Magnetic Resonance Imaging; Methylprednisolone Hemisuccinate; Multiple Sclerosis; Prednisolone; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha | 2008 |
Multiple sclerosis presented acute hearing loss and vertigo.
Topics: Adult; Audiometry, Pure-Tone; Brain; Caloric Tests; Cochlea; Evoked Potentials, Auditory, Brain Stem; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone Hemisuccinate; Multiple Sclerosis; Nystagmus, Optokinetic; Tomography, X-Ray Computed; Vertigo; Visual Acuity | 1994 |
Decreased vitamin B12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone.
Topics: Adult; Female; Folic Acid; Folic Acid Deficiency; Humans; Injections, Intravenous; Male; Methylation; Methylprednisolone Hemisuccinate; Middle Aged; Multiple Sclerosis; Myelin Sheath; Vitamin B 12; Vitamin B 12 Deficiency | 1993 |
Acute aphasia in multiple sclerosis.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Aphasia, Broca; Female; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone Hemisuccinate; Middle Aged; Multiple Sclerosis | 2000 |